Recursion Pharmaceuticals Future Growth
How is Recursion Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score
1/6Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
-11.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 10 | -379 | N/A | N/A | 1 |
| 12/31/2024 | 85 | -260 | -279 | -249 | 5 |
| 12/31/2023 | 71 | -230 | -230 | -202 | 6 |
| 9/30/2022 | 29 | -247 | -134 | -100 | N/A |
| 6/30/2022 | 18 | -234 | -113 | -78 | N/A |
| 3/31/2022 | 13 | -212 | -75 | -50 | N/A |
| 12/31/2021 | 10 | -186 | -198 | -159 | N/A |
| 9/30/2021 | 10 | -147 | -129 | -89 | N/A |
| 6/30/2021 | 9 | -124 | -106 | -75 | N/A |
| 3/31/2021 | 6 | -99 | -84 | -58 | N/A |
| 12/31/2020 | 4 | -87 | -52 | -45 | N/A |
| 12/31/2019 | 2 | -62 | -61 | -57 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RXRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RXRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RXRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RXRX's revenue (14.2% per year) is forecast to grow faster than the US market (7.1% per year).
High Growth Revenue: RXRX's revenue (14.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RXRX is forecast to be unprofitable in 3 years.